Healthpeak Properties Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.74%.
Did DOC Beat Earnings? Q1 2025 Results
Healthpeak Properties kicked off 2025 with a strong first quarter, posting earnings per share of $0.06 against a consensus estimate of $0.04, a beat of 33.33%, while revenue of $702.89 million topped expectations of $689.24 million and climbed 15.9% from the year-ago period. The most material driver behind the improvement was a sharp pullback in transaction and merger-related costs, which fell to $5.53 million from $107.22 million in Q1 2024, as integration expenses from the Physicians Realty Trust merger continued to wind down and the combined portfolio began contributing fully. Same-store cash NOI grew 7.0% on a merger-combined basis, led by the CCRC segment at 15.9%, with lab and outpatient medical also posting solid gains. Leasing momentum remained healthy, with 1.2 million square feet executed across the portfolio during the quarter. Healthpeak reaffirmed its full-year 2025 guidance, targeting diluted EPS of $0.30 to $0.36 and FFO as Adjusted of $1.81 to $1.87 per share, signaling management's confidence in sustained operating momentum through year-end.
- Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 7.0%
- CCRC same-store NOI growth of 15.9%
- Lab same-store NOI growth of 7.7%
- Outpatient Medical same-store NOI growth of 5.0%
- Outpatient medical new and renewal lease executions of 973,000 sq ft with 86% retention and +4% cash releasing spreads
- Lab new and renewal lease executions of 276,000 sq ft with 88% retention and +5% cash releasing spreads
- Significantly lower transaction and merger-related costs ($5.5M vs $107.2M year-ago)
Forward Guidance & Outlook
Healthpeak reaffirmed its full-year 2025 guidance: diluted earnings per common share of $0.30–$0.36, diluted Nareit FFO per share of $1.81–$1.87, diluted FFO as Adjusted per share of $1.81–$1.87, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0%–4.0%.
DOC YoY Financials
DOC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.